A

    Adlai Nortye Ltd. American Depositary Shares (ANL)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $14.19
    +0.37 (+2.68%)

    Market Cap: $889.98M

    Last updated: Sep 01, 2026 at 4:59 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    67%(4/6)
    Avg Surprise
    +11.75%

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$0.03
    Range$0.03 - $0.03
    1 analysts
    EPS RevisionsNo revisions (7d)No revisions (30d)
    EPS Estimate Drift
    90d ago$0.00-100.0%
    60d ago$0.00-100.0%
    30d ago$0.00-100.0%
    7d ago$0.03+0.0%
    Current$0.03
    Revenue Consensus
    $0
    Range$0 - $0
    1 analysts
    Period ending Dec 31, 2026
    EPS Consensus$0.15
    Range$0.00 - $0.26
    6 analysts
    Revenue Consensus
    $14M
    Range$10M - $26M
    6 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$0.15---
    Sep 26EST
    		-$0.03---
    Jun 26
    Reported Aug 6
    		$N/A$-0.35N/ABeat-
    Mar 26
    Reported Apr 10
    		$N/A$0.00N/ABeat-
    Dec 25
    Reported Feb 25
    		$0.00$0.00N/ABeat-
    Sep 25
    Reported Dec 29
    		$0.00$0.00N/ABeat+100.0%
    Jun 25
    Reported Aug 7
    		$-0.18$0.00N/AMiss+72.2%
    Mar 25
    Reported Apr 30
    		$-0.64$-0.63-1.59%Miss-68.4%
    Sep 24
    Reported Nov 27
    		$0.00N/A+100.00%Beat+100.0%
    Jun 24
    Reported Aug 8
    		$-0.35$-0.61+42.62%Beat+82.0%
    Mar 24
    Reported Apr 20
    		$-0.65$-0.38-70.52%Miss-9.7%
    Dec 23
    Reported Mar 30
    		$-0.38$-0.38+0.00%Beat+56.3%
    Sep 23
    Reported Nov 29
    		$-0.24$-0.24+0.00%Beat+72.4%
    Jun 23
    Reported Aug 30
    		$-1.94$0.00N/AMiss-1313.0%
    Mar 23
    Reported Mar 31
    		$-0.59N/AN/ABeat-35.7%
    Dec 22
    Reported Dec 31
    		$-0.87N/AN/ABeat-
    Sep 22
    Reported Sep 30
    		$-0.87N/AN/ABeat-
    Jun 22
    Reported Jun 30
    		$-0.14N/AN/ABeat-
    Mar 22
    Reported Mar 31
    		$-0.44N/AN/ABeat-

    Key Metrics

    Valuation
    P/E Ratio-7.81EV/EBITDAN/A
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin-124.80%Operating Margin-44.20%
    ROE-20.20%ROIC-7.55%
    Financial Health
    Debt/Equity0.09xInterest CoverageN/A
    Current Ratio9.55xQuick Ratio9.55x
    Trading Statistics
    Beta1.12Avg Volume160.16K
    52-Week High$17.2552-Week Low$0.88

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$14.12
    SMA 20$13.66
    SMA 50$12.25
    SMA 200$8.74
    EMA 10$14.01
    EMA 20$13.63
    EMA 50$12.75
    EMA 200$9.47

    MACD

    Line: 0.53Signal: 0.55Hist: -0.02

    ADX

    ADX: 16.6+DI: 18.1-DI: 14.9

    Aroon & PSAR

    Aroon Up92.0
    Aroon Down4.0
    PSAR$15.20

    Bollinger Bands

    Upper Band$14.82
    Lower Band$12.50
    %B Position1697%(Upper)
    Band Width0.73

    RSI (14-Day)

    Neutral
    56.8

    Momentum Oscillators

    Stoch %K59.9
    Stoch %D68.4
    Williams %R-37.1
    ROC (10d)6.4%
    Momentum0.85
    CCI (20d)50.6
    MFI (14d)64.3

    Volatility Measures

    ATR (14d)$1.08(7.6%)
    StdDev (20d)0.58
    Hist Vol60.2%(High)

    Volume Flow

    VWAP$13.96
    OBV49.1M
    AD Line26.2M
    CMF (20d)0.063

    Volume Metrics

    Avg Vol (20d)157.3K
    Vol Ratio0.9x
    VWMA (20d)$13.69

    Pivot Points

    R3$15.27
    R2$14.87
    R1$14.34
    Pivot Point$13.94
    S1$13.41
    S2$13.01
    S3$12.48

    Advanced Oscillators

    TSI17.82
    Ultimate Osc57.2
    KST178.57

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023Dec 2022Sep 2022
    Total Revenue$7.34M$7.34M$2.50M$2.50M$745,000$745,000$2.50M$2.50M$0$0N/AN/A
    Cost of RevenueN/AN/A$0N/AN/AN/AN/AN/A$645,995$532,956N/AN/A
    Gross Profit$7.34M$7.34M$2.50M$2.50M$745,000$745,000$2.50M$2.50M$-645,995$-532,956N/AN/A
    Operating Expenses$10.22M$10.22M$10.76M$10.76M$14.08M$14.08M$15.13M$15.13M$16.86M$15.26M$28.34M$28.34M
    R&D$7.32M$7.32M$8.79M$8.79M$13.01M$13.01M$15.45M$15.45M$13.94M$13.31M$16.29M$16.29M
    SG&A$2.91M$2.91M$2.10M$2.10M$2.36M$2.36M$5.03M$5.03M$3.08M$2.15M$3.00M$3.00M
    Operating Income$-2,884,500$-2,884,500$-8,262,000$-8,262,000$-14,621,500$-14,621,500$-17,713,000$-17,713,000$-16,862,000$-15,263,000$-19,227,500$-19,227,500
    Interest Income$0$0$0$0$0$0$0$0$1,000$64,000$0$0
    Interest Expense$221,500$221,500$0$434,500$0$0$0$0$163,000$80,000$2.89M$2.89M
    Income Before Tax$-2,668,000$-2,668,000$-8,596,500$-8,596,500$-13,806,000$-13,806,000$-12,905,000$-12,905,000$-63,397,000$-15,021,000$-22,115,000$-22,115,000
    Income Tax Expense$0$0$0$0$0$321,500$321,500$321,500$-46,208,000$338,000$0$0
    Net Income$-2,668,000$-2,668,000$-8,596,500$-8,596,500$-13,806,000$-13,806,000$-13,226,500$-13,226,500$-63,397,000$-15,021,000$-22,115,000$-22,115,000
    EBITDA$-2,693,750$-2,693,750$-8,071,249$-8,010,999$-14,355,500$-14,355,500$-17,429,500$-17,429,500$-62,581,000$-14,407,000$-18,979,000$-18,979,000
    EBIT$-2,884,500$-2,884,500$-8,262,000$-8,261,999$-14,621,500$-14,621,500$-17,713,000$-17,713,000$-63,234,000$-14,941,000$-19,227,500$-19,227,500
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about ANL

    News

    Adlai Nortye CFO Ye Xiaofeng Reports Sale of 11,667 ADS in Two Open-Market Transactions

    Adlai Nortye Group Ltd. (NASDAQ:ANL) CFO Ye Xiaofeng sold a total of 11,667 American Depositary Shares (ADS) in two open-market transactions on August 24 and August 26, 2026. The sales were primarily to optimize the reporting person's tax and liquidity management following RSU vesting in April 2026, with tax obligations for the vesting previously met using out-of-pocket cash. After these sales, Ye Xiaofeng directly holds 147,757 ADS.

    Kalkine Media•8/27/26•
    Neutral

    Adlai Nortye Group (Nasdaq:ANL) - Stock Analysis

    This Simply Wall St stock analysis for Adlai Nortye Group (ANL) provides a comprehensive overview, including company financials, growth prospects, and identified risks such as shareholder dilution and volatile share price. Despite past earnings growth, future earnings are forecast to decline, and the company remains unprofitable. The report also details recent news, including clinical trial updates for AN9025 and AN0025, board changes, and funding announcements.

    Simply Wall Street•8/23/26•
    Somewhat-Bearish

    Adlai Nortye Ltd. Sponsored ADR (ANL) Upgraded to Buy: Here's What You Should Know

    Adlai Nortye Ltd. Sponsored ADR (ANL) has been upgraded to a Zacks Rank #2 (Buy), reflecting an upward trend in its earnings estimates. This upgrade suggests an improved earnings outlook for the company, which often correlates with a favorable impact on stock price. The Zacks system highlights the importance of earnings estimate revisions for predicting near-term stock movements, with ANL's upgrade placing it in the top 20% of Zacks-covered stocks.

    Eastern Progress•8/22/26•
    Bullish

    ANL: Static price chart | Adlai Nortye Group Ltd. | US00704R1095

    This page on MarketScreener provides a static price chart for Adlai Nortye Group Ltd. (ANL), a biotechnology and medical research company listed on Nasdaq under the stock symbol US00704R1095. It also includes recent news about the company's name and registered office address changes, along with various financial metrics and analytical tools offered by the platform.

    www.marketscreener.com•8/22/26•
    Neutral

    Adlai Nortye Ltd. will Change its Name to Adlai Nortye Group Ltd

    Adlai Nortye Ltd. announced that effective August 21, 2026, it will officially change its name to Adlai Nortye Group Ltd. This change was published on MarketScreener and S&P Capital IQ. The article also provides a company profile, recent news, and financial data for Adlai Nortye Ltd.

    www.marketscreener.com•8/21/26•
    Neutral

    Frequently Asked Questions About ANL

    Does ANL pay dividends?
    Adlai Nortye Ltd. American Depositary Shares (ANL) does not currently pay a regular dividend.
    What is ANL's market cap?
    Adlai Nortye Ltd. American Depositary Shares (ANL) has a market capitalization of $889.98M with a current stock price of $14.19.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In